Grän Franziska, Azeem Muhammad, Serfling Edgar, Goebeler Matthias, Kerstan Andreas, Muhammad Khalid
Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, 97080 Würzburg, Germany.
Department of Molecular Pathology, Institute of Pathology, University of Würzburg, 97078 Würzburg, Germany.
Int J Mol Sci. 2025 Aug 22;26(17):8125. doi: 10.3390/ijms26178125.
Allergic contact dermatitis (ACD) is a frequent inflammatory skin disease that evolves upon exposure to contact allergens in sensitized individuals. Both the adaptive and innate immune system play pivotal roles in the pathogenesis of ACD. While the importance of T cells is undisputed, the relevance of B lymphocytes is less clear. The published data support a critical role for NFATc1 in B cell activation. Therefore, we investigated the impact of NFATc1 on B cell function during murine contact hypersensitivity (CHS), the mouse model for human ACD. Compared with wild-type mice, B cell-specific ablation of NFATc1 () resulted in significantly diminished CHS responses measured by ear thickness (0.81 ± 0.02 mm vs. 0.48 ± 0.02 mm ( = 0.0007)) to the obligate contact allergen 2,4,6-trinitrochlorobenzene, accompanied by a marked increase in the frequency of IL-10-producing regulatory B cells. Flow cytometric analysis showed that IL-4- and IL-17-producing CD4 T cells were reduced, while IFN-γ-producing CD4 T cells were marginally increased in mice. In conclusion, NFATc1 mediates CHS responses by modulating the development of IL-10-producing B cells. These findings support the compelling notion that targeting NFATc1 may represent a potential therapeutic strategy for allergic responses.
过敏性接触性皮炎(ACD)是一种常见的炎症性皮肤病,在致敏个体接触接触性变应原后发病。适应性免疫系统和固有免疫系统在ACD的发病机制中均起关键作用。虽然T细胞的重要性无可争议,但B淋巴细胞的相关性尚不清楚。已发表的数据支持NFATc1在B细胞活化中起关键作用。因此,我们在小鼠接触性超敏反应(CHS,人类ACD的小鼠模型)过程中研究了NFATc1对B细胞功能的影响。与野生型小鼠相比,NFATc1的B细胞特异性缺失()导致对专性接触变应原2,4,6-三硝基氯苯的CHS反应显著减弱,通过耳厚度测量(0.81±0.02毫米对0.48±0.02毫米(=0.0007)),同时产生IL-10的调节性B细胞频率显著增加。流式细胞术分析显示,在小鼠中,产生IL-4和IL-17的CD4 T细胞减少,而产生IFN-γ的CD4 T细胞略有增加。总之,NFATc1通过调节产生IL-10的B细胞的发育来介导CHS反应。这些发现支持了一个令人信服的观点,即靶向NFATc1可能代表一种针对过敏反应的潜在治疗策略。